Patents Examined by Julie Ha
  • Human sDR5-fc recombinant fusion protein and application thereof
    Patent number: 11220533
    Abstract: An sDR5-Fc recombinant fusion protein having amino acid sequence of SEQ ID NO: 2 and a gene encoding the protein and having a nucleotide sequence as shown in SEQ ID NO: 1 are provided. Further, applications of the protein and the gene in the preparation of medicament for preventing and treating autoimmune hepatitis or drug-induced liver injury are provided.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: January 11, 2022
    Assignee: SHENZHEN ZHONGKE AMSHENN PHARMACEUTICAL CO., LTD.
    Inventors: Xiaochun Wan, Junxin Li, Qian Chen, Qingmei Zhang
  • Compositions and methods for treating pulmonary hypertension
    Patent number: 11220528
    Abstract: Methods treating pulmonary hypertension, including pulmonary arterial hypertension, are provided, and include administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. Administration of the polypeptide antagonist reduces pulmonary artery acceleration time, reduces an amount of right ventricular hypertrophy, reduces right ventricular wall thickness, reduces an amount of pulmonary vessel wall thickness, reduces an amount of plexiform lesions in a lung of the subject, reduces an amount of collagen deposition in a pulmonary blood vessel, reduces an amount of collagen deposition in a pulmonary blood vessel media or adventitia, and/or reduces an amount of right ventricular fibrosis. Methods of reducing pulmonary vessel wall thickness are also provided and include the administration of the polypeptide antagonist of a Na/K ATPase/Src receptor complex.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: January 11, 2022
    Assignee: MARSHALL UNIVERSITY RESEARCH CORPORATION
    Inventors: Zijian Xie, Jiayan Wang, Sandrine V. Pierre, Joseph I. Shapiro
  • Bis-amino acid based compound and use thereof
    Patent number: 11213512
    Abstract: Compositions comprising bis(tryptophan) derivatives are provided that act as antimicrobials. Also provided are methods for reversing antibiotic resistance in a bacterium, or recovering or enhancing antimicrobial activity of an antibiotic against a variety of microbes, by co-administration with a bis(tryptophan) derivative.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: January 4, 2022
    Assignee: The Curators of the University of Missouri
    Inventors: George W Gokel, Joseph W Meisel, Mohit B Patel
  • ZAG-derived peptide and use thereof
    Patent number: 11213567
    Abstract: A zinc-alpha-2-glycoprotein (ZAG) protein-derived peptide according to the present invention shows an expression reducing effect of various immune factors shown in acute or chronic atopic dermatitis, and has a decreased immune response and decreased IgE expression and thus may be used to prevent, treat or improve xeroderma or an abnormal skin barrier function such as atopic dermatitis, an allergic disease or inflammation.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: January 4, 2022
    Assignee: L&C Bio Co., LTD.
    Inventors: Eun Seong Lee, Hyung Gu Kim, Whan Chul Lee, Kee Won Lee
  • Cartilage regeneration composition containing HAPLN1 as active ingredient
    Patent number: 11213572
    Abstract: Provided is a method of regenerating cartilage tissues by treatment with hyaluronan and proteoglycan link protein 1 (HAPLN1), and a composition for regenerating cartilage, the composition including HAPLN1 as an active ingredient. According to the present disclosure, the HAPLN1 protein may have cartilage formation-stimulating ability and articular cartilage regeneration ability, may increase an expression level of TGF-? receptor I of chondrocytes to increase a component ratio of cells having cartilage formation ability, and to induce regeneration of cartilage tissues. Accordingly, the HAPLN1 protein of the present disclosure, which is a novel composition regulating TGF-? signaling, may be usefully applied as a pharmaceutical composition for regenerating cartilage, a health food composition for regenerating cartilage, or a reagent composition for regenerating cartilage.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: January 4, 2022
    Assignee: HAPLNSCIENCE INC.
    Inventors: Dae Kyong Kim, Ji Min Jang
  • Methods and compositions for treating melanoma
    Patent number: 11208468
    Abstract: Compositions and methods for treating melanoma are provided. Compositions include BRAFV600E-based peptides, alone or admixed with T helper peptides. Other compositions include nucleic acid sequences encoding the BRAFV600E-based peptides, alone or admixed with nucleic acid sequences T helper peptides. Dendritic cells pretreated with the BRAFV600E-based peptides, alone or admixed with T helper peptides, are also provided. These compositions are useful to treat melanoma, optionally co-administered with antibodies to checkpoint inhibitors or molecules that mimic the action of such antibodies.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: December 28, 2021
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Rajasekharan Somasundaram, Meenhard Herlyn, Dorothee Herlyn
  • Compositions and methods for modulating ciliogenesis
    Patent number: 11207369
    Abstract: Disclosed herein are methods for modifying ciliogenesis in one or more cells of a subject, the method comprising administering to the subject an effective amount of a composition comprising a Notch signaling inhibitor, wherein the modification results in an increase in a number of cilia, an increase in a length of cilia, and/or an increase in a beat frequency of cilia as compared to a control. Also disclosed herein are methods for modifying ciliogenesis in one or more cells of a subject, the method comprising administering to the subject from 0.1 ?g/kg to 100 g/kg of a Notch signaling inhibitor. In some embodiments, the methods can be used to treat Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Asthma, Primary Ciliary Dyskinesia (PCD), Cystic Fibrosis (CF), or hydrocephalus.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: December 28, 2021
    Assignee: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Maliha Zahid, Cecilia Wen Ya Lo
  • Peptides inhibiting KLK1, KLK4, or KLK4 and KLK8
    Patent number: 11208467
    Abstract: A novel peptide which comprises an amino acid sequence represented by SEQ ID NO: 23, and specifically inhibits the protease activity of a target molecule.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: December 28, 2021
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Masakazu Tamura
  • Composition for improving or preventing nonalcoholic fatty liver
    Patent number: 11207371
    Abstract: An object of the present invention is to provide a composition for preventing or improving fat deposition on the liver in spite of the alcohol intake history of a level that a liver disease is not caused. The inventors found that glutathione has an effect of preventing or improving fat deposition on the liver, which is not caused by alcohol, and completed the present invention. Among nonalcoholic fat diseases, the present invention is particularly effective in an early stage of the treatment or in a case where treatment for another disease is not performed.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: December 28, 2021
    Assignees: KOHJIN LIFE SCIENCES CO., LTD., PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, SAGA UNIVERSITY
    Inventors: Takaomi Kessoku, Atsushi Nakajima, Yoshio Sumida, Yuichiro Eguchi, Susumu Saito, Yusuke Sauchi
  • Cancer treatment drug
    Patent number: 11203615
    Abstract: A peptide that includes a partial amino acid sequence of the C16orf74 protein, includes the cysteine at position 7 and/or the cysteine at position 14 of the C16orf74 protein, and inhibits dimer formation of the C16orf74 protein is provided. A pharmaceutical composition for cancer treatment that includes the peptide is also provided. A screening method for cancer treatment drugs that takes as the indicator inhibition of dimer formation of the C16orf74 protein is also provided.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: December 21, 2021
    Assignee: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventor: Toru Nakamura
  • Composite polypeptide having a metal binding motif and molecular construct comprising the same
    Patent number: 11203614
    Abstract: Disclosed herein are composite polypeptide. According to various embodiments, the composite polypeptide includes a parent polypeptide and a metal binding motif capable of forming a complex with a metal cation. The composite polypeptide may be conjugated with a linker unit having a plurality of functional elements to form a multi-functional molecular construct. Alternatively, multiple composite polypeptides may be conjugated to a linker unit to form a molecular construct, or a polypeptide bundle. Linker units suitable for conjugating with the composite polypeptide having the metal binding motif are also disclosed.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: December 21, 2021
    Assignee: IMMUNWORK INC.
    Inventors: Tse-Wen Chang, Hsing-Mao Chu, Wei-Ting Tian, Yueh-Hsiang Yu
  • Pharmaceutical composition for preventing or treating neovascular disease, containing collagen type i and pigment epithelium derived factor peptide as active ingredients
    Patent number: 11197918
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neovascular disease, including a collagen and a 34-mer pigment epithelium derived factor (PEDF) peptide as an active ingredient, more specifically, the combined administration of the collagen type I and the 34-mer pigment epithelium derived factor peptide increases the short antiangiogenic activity cycle of the PEDF and extends the dosage range of the PEDF to solve the discomfort and the side effects accordingly due to the conventional frequent injections and thus it can be applied as a therapeutic agent for various neovascular diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: December 14, 2021
    Assignee: NexThera Co., Ltd.
    Inventors: Sea Gwang Park, Kug Hwan Roh, Hyun Woong Kim, Sung Jae Park
  • Lyophilized recombinant VWF formulations
    Patent number: 11197916
    Abstract: Long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations are described.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: December 14, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kurt Schnecker, Eva Haidweger, Peter Turecek
  • Peptoids and methods for attenuating inflammatory response
    Patent number: 11197908
    Abstract: Disclosed herein are peptoids and methods for attenuating inflammatory responses, and more particularly RAGE-associated inflammatory responses.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: December 14, 2021
    Assignees: The Board of Trustees of the University of Arkansas, University of South Carolina
    Inventors: Shannon Servoss, Melissa Moss, Lauren Wolf
  • Lyophilized recombinant VWF formulations
    Patent number: 11191813
    Abstract: Long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations are described.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: December 7, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kurt Schnecker, Eva Haidweger, Peter Turecek
  • Cytocidal agent
    Patent number: 11191804
    Abstract: An object of the present invention is to provide a peptide drug that is able to selectively induce apoptosis in target cells. The present invention is a cytocidal agent containing a fusion peptide of an endosome escape peptide and an apoptosis-inducing peptide, which consists of an amino acid sequence represented by SEQ ID NO: 1, and the said cytocidal agent as a therapeutic agent for a disease caused by abnormal proliferation of cells.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: December 7, 2021
    Assignee: FUJITA ACADEMY
    Inventors: Kazuhiro Sugihara, Naohiro Kanayama, Toshiaki Shibata, Yuichiro Onodera
  • Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
    Patent number: 11191818
    Abstract: The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: December 7, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Bruce Ewenstein, Brahm Goldstein, Bernhard Majer, Paolo Rossato, Friedrich Scheiflinger, Marietta Turecek
  • Anti-HIV peptides
    Patent number: 11186614
    Abstract: Simple ?-hairpin peptides in linear and cyclic form that specifically bind to HIV-1 Trans-Activation Response element (HIV-1 TAR), as well as compositions and use thereof are described.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: November 30, 2021
    Assignees: Colorado State University Research Foundation, University of Rochester
    Inventors: Brian R. McNaughton, David W. Crawford, Joseph E. Wedekind, Ivan A. Belashov
  • H3.3 CTL peptides and uses thereof
    Patent number: 11185577
    Abstract: Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: November 30, 2021
    Assignee: The Regents of the University of California
    Inventors: Hideho Okada, Yafei Hou
  • Substance P analog having progenitor cell or stem cell recruiting activity and method for progenitor cell or stem cell recruiting using the same
    Patent number: 11186612
    Abstract: A substance P analog having a progenitor cell or stem cell recruiting activity and a method of recruiting progenitor cells or stem cells using the substance P analog are disclosed. The substance P analog has an effect of recruiting endogenous progenitor cells or stem cells to a wound or disease-occurring site. Thus, the disclosure also describes its use in recruiting progenitor cells or stem cells and a method of regenerating or treating a damaged organ or tissue, or a method of healing a wound.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: November 30, 2021
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Moon Suk Kim, Sang Dun Choi, Seung Hun Park, Masaud Shah